We leverage the power of the innate and adaptive immune systems with the goal of long-term tumor remissions for patients We leverage the power of the innate and adaptive immune systems with the goal of long-term tumor remissions for patients

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Our Approach

Bolt is pioneering a new category of targeted immunotherapies that leverage the precision of antibody targeting with the activation of the innate and adaptive immune systems in the tumor microenvironment.

Patients

BDC-1001 is a HER2 Boltbody™ ISAC that is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors.

Our Team

Bolt is a world-class, inclusive community of fearless innovators committed to delivering transformative treatments to cancer patients with unmet medical needs.

Pipeline

Utilizing our Boltbody™ ISAC approach and myeloid biology expertise, we have a built a robust pipeline of immune-stimulating, myeloid-engaging therapeutics.

Program
(Target)
IndicationPRECLINICALPHASE 1PHASE 2
BOLTBODY™ ISACs
BDC-1001
HER2

HER2-expressing Solid Tumors

  • HER2+ Breast Cancer
  • HER2+ Gastric Cancer
  • HER2-low Breast Cancer

PHASE 1

Multi-arm Phase 1/2 Trial
BDC-2034
CEA
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Breast Cancer

PRECLINICAL

PD-L1

Checkpoint refractory Tumors

  • Non-Small Cell Lung Cancer
  • Head and Neck Cancer
  • Breast Cancer

PRECLINICAL

MYELOID MODULATING AGONIST ANTIBODY
BDC-3042
Dectin-2

Solid Tumors

  • KRAS mutated tumors
  • TP53 mutated tumors

PRECLINICAL

*Dectin-2, also known as TAM1